Sunshine Biopharma Inc. Operating Income Loss

• Sunshine Biopharma Inc. showed a decrease of -21.5% in Operating Income Loss from 2023 to 2024.
• This data is from Sunshine Biopharma Inc.'s annual report (Form 10-K), filed with the SEC on April 1, 2025.
• XBRL data for this metric is available from 2011 to 2024 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 14 years of available data (2011 to 2024), Sunshine Biopharma Inc.'s Operating Income Loss has declined by 945.0%.
• Historical annual values: Fiscal year 2024: -$5.81 million | Fiscal year 2023: -$4.79 million | Fiscal year 2022: -$27.00 million | Fiscal year 2021: -$2.44 million | Fiscal year 2020: -$576.9 thousand | Fiscal year 2019: -$641.6 thousand | Fiscal year 2018: -$1.16 million | Fiscal year 2017: -$857.2 thousand | Fiscal year 2016: -$993.1 thousand | Fiscal year 2015: -$780.3 thousand | Fiscal year 2014: -$1.76 million | Fiscal year 2013: -$1.94 million | Fiscal year 2012: -$706.7 thousand | Fiscal year 2011: -$556.2 thousand.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026